LLY-507: A Highly Selective SMYD2 Inhibitor for Epigenetic and Cancer Research

Executive Summary: LLY-507 is a small molecule inhibitor with <15 nM IC₅₀ against SMYD2, a lysine methyltransferase implicated in cancer and fibrosis (source: product_spec). SMYD2 overexpression is associated with poor prognosis in cancers such as esophageal squamous cell carcinoma (source: paper). LLY-507 shows >100-fold selectivity over other methyltransferases and non-methyltransferase proteins (source: product_spec). In cellular contexts, it potently inhibits SMYD2-mediated p53 methylation with minimal effects on global histone methylation (source: internal_link). LLY-507 is cell-active and enables apoptosis and proliferation assays in both cancer and fibrosis models (source: paper).

Biological Rationale

SMYD2 (SET and MYND domain-containing protein 2) is a lysine methyltransferase that catalyzes monomethylation on histone H3 at Lys36 (H3K36me1) and non-histone targets such as p53 at Lys370. Overexpression of SMYD2 is observed in multiple human malignancies, including esophageal squamous cell carcinoma, and correlates with adverse patient outcomes (paper). Recent studies implicate SMYD2 in the regulation of epithelial-mesenchymal transition (EMT), fibrosis, and inflammation, particularly in the context of cisplatin-induced chronic kidney disease (CKD). Pharmacological SMYD2 inhibition has been shown to attenuate fibrosis, reduce inflammatory cytokines (IL-6, TNF-α), and improve functional injury in preclinical models (paper).

Mechanism of Action of LLY507

LLY-507 binds within the substrate peptide pocket of SMYD2, competitively inhibiting methyltransferase activity. The compound demonstrates an IC₅₀ of <15 nM for SMYD2 enzymatic inhibition, with >100-fold selectivity over other methyltransferase and non-methyltransferase targets (product_spec). In cellular systems, LLY-507 reduces SMYD2-mediated monomethylation of p53 at submicromolar concentrations, while sparing most histone methylation marks, consistent with SMYD2's cytoplasmic localization and substrate preferences (internal_link). This selectivity is critical for dissecting the direct consequences of SMYD2 inhibition in experimental models of cancer progression and fibrosis.

Evidence & Benchmarks

• LLY-507 exhibits an IC₅₀ <15 nM for SMYD2 enzymatic inhibition under in vitro biochemical assay conditions (source: product_spec).
• LLY-507 is >100-fold selective for SMYD2 over a panel of other methyltransferases and common off-targets (source: product_spec).
• In cisplatin-induced CKD mouse models, SMYD2 inhibitors (including LLY-507) significantly reduced renal fibrosis, EMT, and inflammation markers (DOI).
• Cellular assays confirm that LLY-507 suppresses SMYD2-mediated p53 methylation at Lys370 at submicromolar concentrations, with minimal effect on global histone methylation (internal_link).
• LLY-507 inhibits proliferation in liver, breast, and esophageal cancer cell lines in a dose-dependent manner (source: internal_link).
• Pharmacological inhibition of SMYD2 by LLY-507 in renal fibrosis models downregulates pro-fibrotic Smad3/STAT3 phosphorylation and upregulates the renal protective factor Smad7 (DOI).

For further mechanistic details and benchmarking comparisons, see the earlier review on LLY-507, which primarily focuses on oncology applications. This article extends those findings by incorporating recent fibrosis and CKD research.

Applications, Limits & Misconceptions

LLY-507's high selectivity and cell-permeability make it an ideal tool for dissecting SMYD2 function in cancer and fibrotic disease models. It is widely used in apoptosis assays and cancer cell proliferation inhibition studies (internal_link). In renal fibrosis, LLY-507 has been validated to reduce pro-fibrotic signaling and inflammation in vivo and in vitro (DOI). However, LLY-507 is for research use only. There are no reported clinical or in vivo pharmacokinetic data for this compound (source: product_spec).

Common Pitfalls or Misconceptions

• LLY-507 is not suitable for in vivo therapeutic use or clinical application; its use is restricted to laboratory research (source: product_spec).
• The compound is insoluble in water and must be dissolved in DMSO or ethanol at concentrations ≥57.5 mg/mL and ≥54.7 mg/mL, respectively (source: product_spec).
• LLY-507 does not broadly suppress all histone methylation; effects are limited to SMYD2-specific substrates (internal_link).
• Results in CKD/renal fibrosis animal models should not be directly extrapolated to human pathophysiology without further validation (DOI).
• It is not effective for inhibiting methyltransferases other than SMYD2, such as SETD7 or DOT1L (product_spec).

Workflow Integration & Parameters

Protocol Parameters

• apoptosis assay | 0.1–1 μM LLY-507 | cancer/fibrosis cell lines | robust apoptosis induction at submicromolar concentrations | product_spec
• cancer cell proliferation inhibition | 0.1–2 μM LLY-507 | esophageal/liver/breast cancer cell lines | dose-dependent inhibition of proliferation | product_spec
• renal fibrosis model (mouse) | 10 mg/kg LLY-507, i.p. injection | cisplatin-induced CKD model | reduction of fibrosis markers and inflammation | DOI
• protein substrate methylation assay | 10–50 nM LLY-507 | in vitro enzymatic assays | selective SMYD2 inhibition, minimal off-target effects | product_spec
• solubility testing | ≥57.5 mg/mL in DMSO; ≥54.7 mg/mL in ethanol | compound preparation | ensures maximal stock concentration for cell assays | product_spec
• compound storage | -20°C | all research settings | maintains compound stability | product_spec

For a workflow integrating LLY-507 into lysine methylation pathway studies, see the stepwise analysis outlined in this article, which provides strategic guidance for translational research. This dossier adds updated CKD and fibrosis models not covered in the prior work.

Conclusion & Outlook

LLY-507, supplied by APExBIO, is a nanomolar, highly selective SMYD2 inhibitor with proven efficacy in models of cancer and fibrosis. Its selectivity and substrate specificity are validated across multiple independent assays, making it a gold-standard reagent for SMYD2 pathway interrogation. Future work will likely focus on translational validation and pharmacokinetics, as current evidence is limited to preclinical settings (DOI). For further mechanistic and application-specific insights, the article here contrasts LLY-507’s performance with other SMYD2 inhibitors, while this dossier emphasizes experimental parameters and preclinical results.

For detailed product specifications and ordering, refer to the LLY507 B6119 kit page.